Malgorzata Zajac

Expression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic Leukemia.

Background: The programmed death 1 (PD-1) receptor pathway is responsible for the negative regulation of both T and B lymphocytes upon activation of these cells. There is growing evidence that chronic lymphocytic leukemia (CLL) cells exploit the PD-1 ligand (PD-L1) to resist antitumor immune reactions and maintain their survival by shaping their own microenvironment. Methods: We used a quantitative RT-PCR method to analyze PD-L1 gene expression in bone marrow and peripheral blood mononuclear cells, representing the proliferation and accumulation compartments of CLL. Results: PD-L1 expression was found to be significantly higher in 112 CLL patients than in controls. Levels of PD-L1 expression in bone marrow and peripheral blood were comparable and showed a positive correlation. Furthermore, expression of PD-L1 strongly correlated with expression of PD-1 receptor in mononuclear cells from the same compartment, and was not affected by incubation with immunomodulatory drug thalidomide. Conclusion: PD-L1 expression is shared between CLL cells localized in distinct disease compartments, demonstrating that PD-1/PD-L1 a universal target for therapy.

The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia

Programmed death-1 (PD-1) is a negative receptor expressed on lymphocytes including malignant B cells in chronic lymphocytic leukemia (CLL). In this work, we found that patients with CLL had a higher expression of PD-1 transcript (PDCD1) than healthy volunteers (p < 0.0001). PDCD1 expression was comparable between CLL cells from accumulation (peripheral blood) and proliferation (bone marrow) disease compartments. In blood samples of patients with mutated IGHV genes PDCD1 expression was higher than with unmutated IGHV (p = 0.0299). We demonstrated that phosphorylation of SYK and LYN, key B-cell receptor signaling kinases, was independent of PD-1 expression in patients with CLL, while ZAP-70 phosphorylation in negative tyrosine residue 292 showed strong inverse correlation (r = − 0.8, p = 0.0019). No associations between five single nucleotide polymorphisms of PDCD1, their expressions and susceptibility to CLL were found. In conclusion, PD-1 might be an independent, universal marker of CLL cells and a part of their activated phenotype, and subsequently might modulate the function of ZAP-70.

Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia

Mutations of the nucleophosmin-1 (NPM1) gene in cytogenetically normal (CN) acute myeloid leukemia (AML) identify a group of patients with more favorable prognosis. NPM1 encodes three main alternatively spliced isoforms R1(B23.1), R2(B23.2), and R3(B23.3). The expression of splice variants R1, R2 and R3 were higher in AML patients compared to normal cells of healthy volunteers (HVs), although RNA-seq analysis revealed enhanced R2 expression also in less differentiated cells of HVs as well as in AML cells. The variant R2, which lacks exons 11 and 12 coding for the nucleolar localization domain, might behave similar to the mutant form of NPM1 (NPM1mut). In accordance, in CN-AML high R2 expression was associated with favorable impact on outcome. Moreover, functional studies showed nucleolar localization of the eGFP-NPM1 wildtype and cytoplasmic localization of the eGFP-NPM1 mut protein. While the eGFP-NPM1 R2 splice variant localized predominantly in the nucleoplasm, we also could detect cytoplasmic expression for the R2 variant. These results support a unique biological consequence of R2 overexpression and in part explain our clinical observation, where that high R2 variant expression was associated with a better prognosis in CN-AML patients.

Specific cytotoxic T-cell immune responses against autoantigens recognized by chronic lymphocytic leukaemia cells

Mounting evidence suggests that autoreactivity and inflammatory processes are involved in the pathogenesis of chronic lymphocytic leukaemia (CLL). Cytoskeletal proteins, including non‐muscle myosin heavy chain IIA (MYHIIA), vimentin (VIM) and cofilin‐1 (CFL1), exposed on the surface of apoptotic cells have been identified as autoantigens that are recognized by the specific B‐cell receptors of the CLL cells. In 212 CLL patients analysed with quantitative reverse transcriptase‐polymerase chain reaction

Indirect induction of regulatory T cells accompanies immune responses during peptide vaccination of chronic lymphocytic leukaemia patients.

Keywords: chronic lymphocytic leukaemia; thalidomide; T regulatory cells; interleukin 2; peptide vaccination

Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells

A cute myeloid leukemia is a malignant disease of immature myeloid cells. Despite significant therapeutic effects of differentiation-inducing agents in some acute myeloid leukemia subtypes, the disease remains incurable in a large fraction of patients. Here we show that SK053, a thioredoxin inhibitor, induces differentiation and cell death of acute myeloid leukemia cells. Considering that thioredoxin knock-down with short hairpin RNA failed to exert antiproliferative effects in one of the acute myeloid leukemia cell lines, we used a biotin affinity probe-labeling approach to identify potential molecular targets for the effects of SK053. Mass spectrometry of proteins precipitated from acute myeloid leukemia cells incubated with biotinylated SK053 used as a bait revealed protein disulfide isomerase as a potential binding partner for the compound. Biochemical, enzymatic and functional assays using fluorescence lifetime imaging confirmed that SK053 binds to and inhibits the activity of protein disulfide isomerase. Protein disulfide isomerase knockdown with short hairpin RNA was associated with inhibition of cell growth, increased CCAAT enhancer-binding protein α levels, and induction of differentiation of HL-60 cells. Molecular dynamics simulation followed by the covalent docking indicated that SK053 binds to the fourth thioredoxin-like domain of protein disulfide isomerase. Differentiation of myeloid precursor cells requires the activity of CCAAT enhancer-binding protein α, the function of which is impaired in acute myeloid leukemia cells through various mechanisms, including translational block by protein disulfide isomerase. SK053 increased the levels of CCAAT enhancer-binding protein α and upregulated mRNA levels for differentiation-associated genes. Finally, SK053 decreased the survival of blasts and increased the percentage of cells expressing the maturation-associated CD11b marker in primary cells isolated from bone marrow or peripheral blood of patients with acute myeloid leukemia. Collectively, these results provide a proof-of-concept that protein disulfide isomerase inhibition has potential as a therapeutic strategy for the treatment of acute myeloid leukemia and for the development of small-molecule inhibitors of protein disulfide isomerase.

Expression of CD274 (PD-L1) is associated with unfavourable recurrent mutations in AML

large B-cell lymphoma. Cancer, 15, 3145–3151. Coleman, M., Martin, P., Ruan, J., Furman, R., Niesvizky, R., Elstrom, R., George, P., Kaufman, T.P. & Leonard, J.P. (2008) Prednisone, etoposide, procarbazine, and cyclophosphamide(PEPC) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer, 112, 2228– 2232. Czuczman, M.S., Trn en y, M., Davies, A., Rule, S., Linton, K.M., Wagner-Johnston, N., Gascoyne, R.D., Slack, G.W., Brousset, P., Eberhard, D.A., Hernandez-Ilizaliturri, F.J., Salles, G., Witzig, T.E., Zinzani, P.L., Wright, G.W., Staudt, L.M., Yang, Y., Williams, P.M., Lih, C.J., Russo, J., Thakurta, A., Hagner, P., Fustier, P., Song, D. & Lewis, I.D. (2017) A phase 2/3 Multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clinical Cancer Research, 23, 4127–4137. Mandelli, F., Biagini, C., Baroni, C.D., Bosman, C., Anselmo, A.P., de Luca, A.M., Granati, L., Petti, N. & Papa, G. (1980) Treatment of non Hodgkin’s lymphoma with ROVECIP (procarbazine, vinblastine, cyclophosphamide and prednisone). Haematologica, 65, 107–118. Merli, F., Luminari, S., Rossi, G., Mammi, C., Marcheselli, L., Ferrari, A., Spina, M., Tucci, A., Stelitano, C., Capodanno, I., Fragasso, A., Baldini, L., Bottelli, C., Montechiarello, E., Fogazzi, S., Lamorgese, C., Cavalli, L. & Federico, M. (2014) Fondazione Italiana Linfomi. Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. Leukaemia & Lymphoma, 55, 38–43. Pasquier, E., Kavallaris, M. & Andr e, N. (2010) Metronomic chemotherapy: new rationale for new directions. Nature Reviews Clinical Oncology, 7, 455–465. Zeng, J., Yang, L., Huang, F., Hong, T., He, Z., Lei, J., Sun, H., Lu, Y. & Hao, X. (2016) The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves responserates and progression-free survival in patients with relapsed or refractory nonHodgkin’s lymphoma. Cancer Chemotherapy and Pharmacology, 78, 801–808.